T1	Disorder 23 47	type 2 diabetes mellitus
N1 	Reference T1 UMLS:C0011860	type 2 diabetes mellitus
T2	Pharmacological_substance 53 63	glitazones
N1000 	Reference T2 MeSH:D045162	glitazones
T5	Disorder 88 112	Type 2 diabetes mellitus
N2 	Reference T5 UMLS:C0011860	Type 2 diabetes mellitus
T6	Disorder 331 342	retinopathy
N3 	Reference T6 UMLS:C0035309	retinopathy
T7	Disorder 344 355	nephropathy
N4 	Reference T7 UMLS:C0022658	nephropathy
T8	Disorder 361 371	neuropathy
N5 	Reference T8 UMLS:C0442874	neuropathy
T10	Disorder 432 468	macrovascular cardiovascular disease
T11	Disorder 498 521	atherosclerotic disease
N6 	Reference T11 UMLS:C0004153	atherosclerotic disease
T14	Disorder 590 618	pathophysiologic abnormality
T17	Disorder 731 744	hyperglycemia
N7 	Reference T17 UMLS:C0020456	hyperglycemia
T18	Disorder 755 767	dyslipidemia
N8 	Reference T18 UMLS:C0242339	dyslipidemia
T19	Disorder 769 781	hypertension
N9 	Reference T19 UMLS:C0020538	hypertension
T20	Disorder 783 799	hypercoagulation
N10 	Reference T20 UMLS:C0398623	hypercoagulation
T21	Disorder 830 868	atherosclerotic cardiovascular disease
N11 	Reference T21 UMLS:C0004153	atherosclerotic cardiovascular disease
T22	Disorder 886 909	metabolic abnormalities
T24	Disorder 952 988	cardiovascular dysmetabolic syndrome
T25	Pharmacological_substance 994 1012	thiazolidinediones
N1001 	Reference T25 MeSH:D045162	thiazolidinediones
T26	Pharmacological_substance 1014 1027	rosiglitazone
N1002 	Reference T26 MeSH:C089730	rosiglitazone
T27	Pharmacological_substance 1032 1044	pioglitazone
N1003 	Reference T27 MeSH:C060836	pioglitazone
T28	Pharmacological_substance 1067 1086	antidiabetic agents
N1004 	Reference T28 MeSH:D007004	antidiabetic agents
T33	Disorder 1211 1230	insulin sensitivity
N12 	Reference T33 UMLS:C0571622	insulin sensitivity
N13 	Reference T33 UMLS:C0571622	insulin sensitivity
T38	Disorder 1358 1394	cardiovascular dysmetabolic syndrome
T41	Pharmacological_substance 1485 1495	glitazones
N1005 	Reference T41 MeSH:D045162	glitazones
T42	Disorder 1527 1565	atherosclerotic cardiovascular disease
N14 	Reference T42 UMLS:C0004153	atherosclerotic cardiovascular disease
T43	Disorder 1582 1587	death
N15 	Reference T43 UMLS:C1306577	death
T3	Pharmacological_substance 67 86	insulin sensitizers
T15	Disorder 801 813	vasculopathy
N16 	Reference T15 UMLS:C0042373	vasculopathy
T31	Disorder 300 327	microvascular complications
N17 	Reference T31 UMLS:C0009566	microvascular complications
T34	Disorder 406 422	type 2 diabetics
N18 	Reference T34 UMLS:C0011860	type 2 diabetics
T37	Disorder 622 637	type 2 diabetes
N19 	Reference T37 UMLS:C0011860	type 2 diabetes
T39	Disorder 1567 1576	morbidity
T48	Disorder 553 571	insulin resistance
N20 	Reference T48 UMLS:C0021655	insulin resistance
T49	Disorder 669 687	insulin resistance
N21 	Reference T49 UMLS:C0021655	insulin resistance
T50	Disorder 930 948	insulin resistance
N22 	Reference T50 UMLS:C0021655	insulin resistance
T51	Disorder 1160 1178	insulin resistance
N23 	Reference T51 UMLS:C0021655	insulin resistance
T52	Pharmacological_substance 1094 1112	nsulin sensitizers
T60	Speculation_cue 1496 1499	can
